These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1130 related articles for article (PubMed ID: 32324502)

  • 1. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
    Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
    Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-1 blockade in cardiovascular disease: an appraisal of the evidence across different inflammatory paradigms.
    Bonaventura A; Moroni F; Golino M; Del Buono MG; Vecchié A; Potere N; Abbate A
    Minerva Cardiol Angiol; 2024 Oct; 72(5):477-488. PubMed ID: 37705370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NLRP3 inflammasome as a key driver of vascular disease.
    Takahashi M
    Cardiovasc Res; 2022 Jan; 118(2):372-385. PubMed ID: 33483732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes.
    Buckley LF; Libby P
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):297-305. PubMed ID: 31356538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
    Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
    Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the NLRP3 inflammasome in cardiovascular diseases.
    Toldo S; Mezzaroma E; Buckley LF; Potere N; Di Nisio M; Biondi-Zoccai G; Van Tassell BW; Abbate A
    Pharmacol Ther; 2022 Aug; 236():108053. PubMed ID: 34906598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
    Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
    Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction.
    Takahashi M
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):188-193. PubMed ID: 31356542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases.
    Toldo S; Abbate A
    Nat Rev Cardiol; 2024 Apr; 21(4):219-237. PubMed ID: 37923829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NLRP3 inflammasome in acute myocardial infarction.
    Toldo S; Abbate A
    Nat Rev Cardiol; 2018 Apr; 15(4):203-214. PubMed ID: 29143812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NLRP3 Inflammasome in Acute Myocardial Infarction.
    Mauro AG; Bonaventura A; Mezzaroma E; Quader M; Toldo S
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):175-187. PubMed ID: 31356555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease.
    Vecchié A; Del Buono MG; Chiabrando GJ; Dentali F; Abbate A; Bonaventura A
    Curr Cardiol Rep; 2021 Oct; 23(11):157. PubMed ID: 34599390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
    J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
    Grebe A; Hoss F; Latz E
    Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
    Martínez GJ; Celermajer DS; Patel S
    Atherosclerosis; 2018 Feb; 269():262-271. PubMed ID: 29352570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Pharmacology of the NLRP3 Inflammasome.
    Abbate A; Booz GW
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):173-174. PubMed ID: 31498192
    [No Abstract]   [Full Text] [Related]  

  • 17. Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice.
    Zhao J; Wang Z; Yuan Z; Lv S; Su Q
    Diab Vasc Dis Res; 2020; 17(6):1479164120977441. PubMed ID: 33269624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NLRP3 Inflammasome as a Pharmacological Target.
    Marchetti C
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin-1.
    Del Buono MG; Bonaventura A; Vecchié A; Moroni F; Golino M; Bressi E; De Ponti R; Dentali F; Montone RA; Kron J; Lazzerini PE; Crea F; Abbate A
    Eur J Clin Invest; 2024 Feb; 54(2):e14110. PubMed ID: 37837616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models.
    Das B; Sarkar C; Rawat VS; Kalita D; Deka S; Agnihotri A
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.